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taking typical APDs (all P<0.01). Moreover, individuals taking clozapine showed better language
performance than those taking risperidone (P<0.01). Immediate memory and delayed memory were
modestly correlated with the types of APDs and the PANSS negative scores. Our results show that individuals
taking clozapine performed worse in immediate and delayed memory than those taking typical APDs, but
exemplified better language performance than those taking risperidone.
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Abstract
Cognitive deficits are a core feature of schizophrenia. There is ongoing debate about
whether cognition is affected by antipsychotic drugs (APDs). This study examined the
effect of long-term treatment with APDs on cognition in schizophrenia. Cognitive
function was assessed in 418 patients with schizophrenia on long-term treatment with
APDs (215 on clozapine, 91 on risperidone, and 112 on typical APDs) and 159 healthy
controls using the Repeatable Battery for the Assessment of Neuropsychological Status
(RBANS). Schizophrenia symptomatology was assessed using the Positive and
Negative Syndrome Scale (PANSS). We found that cognitive test scores were
significantly lower in all patient subjects compared to healthy controls on almost all of
the

total

and

subscores

of

RBANS

(all

p<0.001)

except

for

the

visuospatial/constructional index. Individuals taking clozapine showed worse
immediate and delayed memory performance than those taking typical APDs (all
p<0.01). Moreover, individuals taking clozapine showed better language performance
than those taking risperidone (p<0.01). Immediate memory and delayed memory were
modestly correlated with the types of APDs and the PANSS negative scores. Our results
show that individuals taking clozapine performed worse in immediate and delayed
memory than those taking typical APDs, but exemplified better language performance
than those taking risperidone.

Keywords: Schizophrenia, Cognitive deficits, Antipsychotic drugs, Treatment
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Introduction
Cognition in schizophrenia is impaired across multiple domains, including memory,
attention, processing speed, and executive function (Keefe and Harvey, 2012; Vyas et
al., 2011). Cognitive impairment in schizophrenia is directly related to socio-vocational
function, which can have a greater adverse effect on brain function than the positive or
negative symptoms of schizophrenia (Velligan et al., 2000). Cognitive impairment
significantly affects the acquisition of new skills, limits or prevents employment, and
seriously reduces patients’ quality of life (Sidlova et al., 2011; Tomida et al., 2010).
Currently, the pathophysiological mechanism of cognitive deficits in patients with
schizophrenia is unclear. Antipsychotic drugs (APDs) are usually prescribed to treat
schizophrenia. However, the effects of APDs on cognitive deficits remain controversial
for patients with schizophrenia on long-term medication (Daban et al., 2005; Keefe and
Harvey, 2012; Thornton et al., 2006; Woodward et al., 2005).

Previous studies have shown that cognitive function in patients with schizophrenia
could be influenced by APDs (Beninger et al., 2010; Terry and Mahadik, 2007). For
example, some studies have suggested that APDs induce distinct regionalized neural
responses in different brain regions that are associated with distinct cognitive functions
(Beninger et al., 2010; Westerink, 2002). Moreover, some studies have shown that
APDs, in particular atypical APDs, are associated with the improvement in some
cognitive deficits in patients with schizophrenia, especially executive function, spatial
memory, processing speed, and attention (Hill et al., 2010; Keefe et al., 2006; Meltzer
and McGurk, 1999; Woodward et al., 2005). Furthermore, a meta-analytic study
supported that the inherent anticholinergic property of APDs may affect long-term
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memory in patients with schizophrenia (Thornton et al., 2006). An animal study also
indicated that APDs had a negative effect on cognition, especially for long-term
administrations (Terry and Mahadik, 2007). However, some studies did not find that
APDs had a major effect on cognition in patients with schizophrenia (Daban et al.,
2005; Lindenmayer et al., 1998). In addition, a few studies investigating the effects of
APD treatments on language and immediate and delayed memory in patients with
schizophrenia were inconclusive (Meltzer and McGurk, 1999; Minzenberg et al., 2004;
Takeuchi et al., 2013). Thus, whether APDs affect cognition in patients with chronic
schizophrenia, especially language and immediate and delayed memory, deserves
further investigation.

A few studies have investigated the effects of clozapine on cognition in patients with
schizophrenia, and have shown a mixture of beneficial, deleterious or absent effects
(Hoff et al., 1996; Lindenmayer et al., 1998; Sharma et al., 2003; Thornton et al., 2006).
A growing body of evidence suggests that the inherent anticholinergic properties of
some APDs might limit gains or impair memory-related task performance, as well as
alter central cholinergic function (Minzenberg et al., 2004; Terry and Mahadik, 2007;
Thornton et al., 2006). A radioligand binding study has shown that clozapine has the
highest affinity for all muscarinic M1-5 receptors compared to other APDs, with the
highest affinity for the M1 receptor (Bymaster et al., 2003). Although clozapine was
found to have a weak partial agonist activity at the muscarinic M1 and M4 receptors,
particularly the M4 receptors, both in vitro and in vivo studies have indicated that
clozapine functions as an antagonist at the muscarinic M1 and M4 receptors (Bymaster et
al., 2003). Therefore, it is important to understand whether clozapine has a specific
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impairment effect on cognition compared to other APDs in patients with schizophrenia
during long-term medication, especially in relation to memory-related task performance.

Although risperidone is an atypical APD, it has a higher affinity and longer dissociation
latency period for the D2 receptors than other atypical APDs such as clozapine (Kapur
and Seeman, 2001). These properties may contribute to risperidone’s some similar
effects to typical APDs in treating patients with schizophrenia (Houthoofd et al., 2008).
Unlike clozapine, risperidone does not have a significant affinity with the muscarinic
M1-5 receptors (DeLeon et al., 2004). Risperidone has been associated with improved
and clozapine with worsened memory performance in patients with schizophrenia
(Houthoofd et al., 2008). Another study has shown that clozapine improved language
more than risperidone (Meltzer and McGurk, 1999). However, some studies have not
supported the improvement effects of clozapine on language and risperidone on
memory (Buchanan et al., 1994; Stip and Lussier, 1996). Thus the effects of risperidone
and clozapine on cognitive function in patients with schizophrenia deserve further
investigation, especially in relation to memory and language.

In addition, compared to risperidone and typical APDs, clozapine has also been
associated with substantial weight gain, increased serum triglyceride levels, and an
increased risk of diabetes (Flanagan, 2008; Nasrallah, 2003). This may independently
augment the risk of cognitive deficits. Therefore, it is important to understand the
differences of cognitive deficits in patients with chronic schizophrenia during long-term
clozapine, risperidone, and typical APDs treatment.
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This study aimed to investigate whether: (1) individuals taking different APDs for
chronic schizophrenia presented different cognitive deficits during long-term
medication; (2) individuals taking clozapine showed worse memory performance than
risperidone or other typical APDs; (3) individuals taking clozapine indicated better
language performance than risperidone or other typical APDs.

Methods
Participants
A total of 418 patients with chronic schizophrenia were recruited using a cross-sectional
design in Beijing Hui-Long-Guan Hospital, a Beijing City owned psychiatric hospital.
The diagnosis for each patient was made by two independent and experienced
psychiatrists and confirmed by the Structured Clinical Interview for DSM-IV (SCID).
All patients were aged between 25 and 70 years, diagnosed with schizophrenia for at
least 5 years, and were on stable doses of oral APDs for at least 6 months prior to entry
into the study. The antipsychotic treatments for the patients were given by their
psychiatrist. The treatments were not changed when they were recruited. Antipsychotic
treatment consisted mainly of monotherapy with clozapine (n=215), risperidone (n=91),
and typical APDs (n=112), including haloperidol (n=28), chlorpromazine (n=32),
perphenazine (n=24), and sulpiride (n=28). “The mean dose of each antipsychotic drug
used in the study were 365.3±168.3 mg/day (200-700 mg/day) for clozapine, 4.9±1.4
mg/day (2-7mg/day) for risperidone, 22±15 mg/day (4-40 mg/day) for haloperidol,
367±163 mg/day (150-700 mg/day) for chlorpromazine, 24±17 mg/day (10-40 mg/day)
for perphenazine and 538±266 mg/day (200-1100 mg/day) for sulpiride. The detailed
doses for chlorpromazine equivalents for each drug were presented in Table 2”. The
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mean antipsychotic dose was converted to approximate daily mean chlorpromazine
milligram equivalents for each patient using standard guidelines (Woods, 2003).
Patients were hospitalized for an average of 10.7±8.5 years.

One hundred and fifty nine healthy controls were recruited during the same period from
the Beijing community. Psychiatric disorders in the healthy controls were ruled out with
a psychiatric interview conducted by a psychiatrist.

We obtained a complete medical history, physical examination, and laboratory tests
from all subjects. All healthy controls were in good physical health. All patients were
free from other physical diseases, including diseases of the central nervous system,
stroke, tumours, Parkinson’s disease, Huntington’s disease, seizure disorders, history of
brain trauma, and acute and chronic infections. Neither patients nor healthy controls
suffered from drug or alcohol abuse/dependence. Any subjects with a diagnosis of
dementia or mild cognitive impairment (MCI) were excluded. The subjects were all
from the Han Chinese population. All patients gave signed, informed consent to
participate in the study, which was approved by the Institutional Review Board of the
Beijing Hui-Long-Guan Hospital.

Clinical assessment
Four experienced psychiatrists, who were blind to the clinical status of patients,
assessed the severity of the patients’ psychopathology using the Positive and Negative
Syndrome Scale (PANSS). The PANSS comprises the positive symptoms, negative
symptoms, general psychopathology, and PANSS total score (Kay et al., 1987). To
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ensure consistent and reliable ratings, the four psychiatrists simultaneously attended a
training session for standardizing their use of the PANSS prior to the start of the study.
Thereafter, they maintained an intra-class correlation coefficient of greater than 0.84 on
the PANSS at repeated assessments throughout the study.

Cognitive tests
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),
used to measure cognitive function, was individually administered by trained
investigators and supervised by a research psychiatrist (Duff et al., 2008). It consisted of
12 subtests used to calculate five age-adjusted index scores and a total score (Randolph
et al., 1998). Test indices were: immediate memory (composed of list learning and story
memory tasks); visuospatial/constructional (composed of figure copy and line
orientation tasks); language (composed of picture naming and semantic fluency tasks);
attention (composed of digit span and coding tasks); and delayed memory (composed of
list recall, story recall, figure recall, and list recognition tasks). Our group has
previously translated RBANS into Chinese and its clinical validity and test-retest
reliability have already been established among controls and schizophrenia patients
(Zhang et al., 2009). To ensure consistent and reliable ratings, the two clinical
psychiatrists simultaneously attended a training session to standardize their use of the
RBANS prior to the study. Thereafter, they maintained an intra-class correlation
coefficient of 0.92 on the RBANS at repeated assessments throughout the study.

Statistical analysis
Group comparisons on demographic and clinical variables used Chi squared or Fisher
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exact tests for categorical variables and analysis of variance (ANOVA) for continuous
variables. Post-hoc comparisons between subgroups were made using the Tukey’s
honestly significant difference (HSD) procedure. For the RBANS comparisons, we also
included age, gender, education, smoking, dose and duration of APDs treatment, and
anti-Parkinsonian drugs as covariates in the multivariate analyses of covariance
(MANCOVA). Multiple regression models were used to quantify the amount of
variance in cognitive functioning explained by the psychopathological variables after
controlling for several potential confounders, such as gender, age, education, and
clinical variables. All statistical analyses and database manipulations were performed
with SPSS version 18.0 (SPSS Inc., USA). Data were presented as mean±SD. All pvalues were two-tailed at the significant level of p<0.05.

Results
Demographic and clinical information
Table 1 shows no significant differences among the four examined groups in gender,
age, education, body mass index (BMI), smoking, and incidence of diabetes (all
p>0.05). Patients taking clozapine had significantly higher triglyceride levels than
risperidone and typical APDs (p<0.01). Moreover, patients taking clozapine had
significantly lower high density lipoprotein than typical APDs (p<0.01). There were no
significant differences among patients taking clozapine, risperidone, and typical APDs
in fasting blood glucose, cholesterol, and low density lipoprotein. Furthermore, there
were no significant differences in any PANSS scores, duration of illness, and APD dose
(chlorpromazine CPZ equivalents). However, patients taking clozapine showed

10

significantly lower anti-Parkinsonian drugs used than risperidone and typical APDs
(p<0.001) (Table 2).

Cognitive performance in patients with chronic schizophrenia on long-term
treatment with clozapine, risperidone, and typical APDs
RBANS cognitive index scores for all subjects are summarized in Table 3. After
controlling the age, education, gender, and smoking, the multivariate analysis of
covariance revealed that all patients had significantly lower cognitive scores than
healthy controls in almost all of the total and subscores of RBANS (all p<0.001), except
for the visuospatial/constructional index. Furthermore, five subscores of RBANS were
compared among clozapine, risperidone and typical antipsychotic treatment groups after
adjustment for demographic data, clinical symptoms, antipsychotic drug dose and
antiparkinsonian drugs. Immediate memory score showed 7.5% decrease in individual
taking clozapine (58.3±16.6) than typical APDs (62.7±16.8) (p<0.01). Delay memory
score were 7.1% decrease in individual taking clozapine (66.2±19.7) than typical APDs
(70.9±20.4) (p<0.01). Language score indicated 8.4% decrease in individual taking
clozapine (84.5±15.6) than risperdone (78.6±17.4) (p<0.01). Also, individuals taking
risperidone showed a decreased trend than typical APDs in immediate (p=0.071) and
delayed memory (p=0.051).

Associations of cognitive impairment with clinical variables in patients with
chronic schizophrenia on long-term treatment with APDs
The associations of cognitive impairment with clinical psychopathological variables
were further examined in patients with schizophrenia. Multivariate regression analysis
showed that the following variables were independently associated with the RBANS

11

total scores: PANSS negative score (beta=-0.37, t=-6.08, p<0.001); PANSS general
symptom score (beta=0.13, t=2.2, p<0.05); education (beta=0.15, t=3.03, p<0.01); and
gender (beta=0.14, t=-2.64, p<0.01). These factors together predicted 16.4% of the
variance of the RBANS total scores.

Furthermore, the subscores of RBANS were analysed separately to assess the effects of
the clinical characteristics associated with cognitive impairment. Multivariate regression
analyses showed that the following variables were independently associated with: (1)
immediate memory: PANSS negative score (beta=-0.23, t=-4.4, p<0.001), education
(beta=0.11, t=2.17, p<0.05), age (beta=-018, t=-3.3, p<0.001), gender (beta=0.17,
t=3.30, p<0.001), and types of APDs (beta=0.18, t=3.60, p<0.001); (2) delayed
memory: PANSS negative score (beta=-0.27, t=-5.14, p<0.001), gender (beta=0.14,
t=2.67, p<0.01), education (beta=0.11, t=2.09, p<0.05), and types of APDs (beta=0.14,
t=2.76, p<0.01); and (3) language: PANSS negative score (beta=-0.34, t=-6.67,
p<0.001), and education (beta=0.15, t=3.00, p<0.01).

Discussion
This study found that all patients showed significant cognitive deficits compared to
healthy controls in almost all examined cognitive domains, except for the
visuospatial/constructional index. In particular, individuals taking clozapine showed
worse immediate and delayed memory than typical APDs, and better language
performance than risperidone.
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Cognitive deficits were significantly different for patients with chronic schizophrenia
during long-term treatment with clozapine, risperidone, or typical APDs. These results
are supported by other studies (Beninger et al., 2010; Hill et al., 2010; Terry and
Mahadik, 2007). Though this study was cross-sectional design, it was random and
therefore might provide robust evidence that APDs may influence cognition in patients
with chronic schizophrenia on long-term medication. Therefore, more research is
required to investigate the pharmacological effects of APDs on cognition.

Interestingly, individuals taking clozapine showed 7.5% and 7.1% decrease in
immediate and delayed memory than typical APDs in patients with chronic
schizophrenia during long-term medication. Moreover, multivariate regression analysis
showed that immediate memory and delayed memory were modestly correlated with the
types of APDs. These results support that clozapine might have worse effects than
typical APDs on immediate and delayed memory for patients with chronic
schizophrenia during long-term medication, which is supported by human and animal
studies (Addy and Levin, 2002; Goldberg et al., 1993; Pocivavsek et al., 2006).
Currently, we cannot provide a reasonable explanation for these results. However, some
studies have shown that the inherent anticholinergic properties of some APDs may be
involved in memory impairment during long-term medication in patients with
schizophrenia (Minzenberg et al., 2004; Terry and Mahadik, 2007; Thornton et al.,
2006). Moreover, one study suggested that decreased activity in the central cholinergic
system was involved in the pathophysiology of schizophrenia and cognitive deficits
(Perry and Perry, 1995). Increasing the activity of the central cholinergic system is
related to the pharmacotherapy of schizophrenia and may have beneficial effects in
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improving memory-related cognitive deficits (Bymaster et al., 2003; Simosky et al.,
2003). Furthermore, one study found that low doses of muscarinic antagonists such as
scopolamine and atropine can lead to inattention and memory impairment (Perry and
Perry, 1995). Other studies found that cognition such as immediate and working
memory may be significantly improved after withdrawal of anticholinergic drugs in
patients with schizophrenia (Mori et al., 2002; Desmarais et al.. 2012). Clozapine has a
high affinity with the muscarinic M1-5 receptors (Bymaster et al., 2003), and appears to
function predominantly as an antagonist at the muscarinic M1 and M4 receptors
(Bymaster et al., 2003). Taken together, these studies show that the stronger inherent
anticholinergic properties of clozapine rather than typical APDs may at least partly
contribute to worsened immediate and delayed memory for patients with chronic
schizophrenia during long-term medication. In addition, animal studies have shown that
clozapine inhibits nicotine binding at the nicotinic α7 acetylcholine receptors and
inhibits downstream catecholamine secretion (Park et al., 2001). This inhibition of the
nicotinic acetylcholine receptors by clozapine and its downstream effects could lead to
memory impairment (Park et al., 2001), suggesting that the potent anticholinergic
properties of clozapine on the nicotinic pathway may also have a role in immediate and
delayed memory impairment in patients with schizophrenia during long-term
medication. Finally, compared with typical APD treatments, patients taking clozapine
showed significantly increased triglyceride levels and decreased high density
lipoprotein (Table 1), which may also lead to worsened immediate and delayed memory
for individuals taking clozapine than typical APDs in patients with schizophrenia
(Perlmuter et al., 1988; Umegaki et al., 2014).
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Another finding from this study is that individuals taking clozapine showed 8.4%
improvement in language performance than risperidone in patients with schizophrenia
during long-term medication. This result is supported by other studies (Meltzer and
McGurk, 1999; Woodward et al., 2005). This study measured cognitive function in the
language domain using picture naming and semantic fluency tasks. Importantly,
semantic fluency tasks are one of an important components of neuropsychological
screenings for executive functioning and processing speed, which are significantly
impaired cognitive domains in patients with schizophrenia (Gleissner and Elger, 2001).
Therefore, this study implies that clozapine may be more effective than risperidone in
improving executive functioning and processing speed in patients with schizophrenia.
The fact that individuals taking clozapine showed better language than risperidone
cannot be explained currently. We hypothesize that as clozapine has a significantly
lower affinity with the D2 receptor than risperidone, it may result in fewer effects of the
D2 antagonist in the fronto-striatal system (DeLeon et al., 2004). However, as this is a
hypothesis, it is important to investigate the effects of the two antipsychotic drugs on
the D2 receptors with in vivo studies in the frontal cortex and hippocampal brain regions
related to language, executive function, and processing speed (Gleissner and Elger,
2001). This may be helpful in elucidating the pharmacological effects which causes
individuals taking clozapine to have better language than risperidone. It is important to
point out that risperidone at 6 mg per day is the lowest dose, which produces substantial
changes to negative symptoms, but does not increase extrapyramidal symptoms (EPS)
(Schooler, 1994). Respirodone at dose above 6mg per day have been reported to
increase EPS, which may affect cognition in patients with schizophrenia (Suzuki, et al.,
2014). Therefore, different doses of risperidone could vary in the effect on cognition in
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patients with schizophrenia. The dose for risperidone used in this study was almost all
less than 6mg per day for patients with schizophrenia. The cognitive effects of
risperidone at dose above 6 mg per day warrant further investigation.

It is worthy of noting that a number of studies have reported that clozapine has
significant advantage than risperidone and typical antipsychotics for the improvement
of negative symptoms (McEvoy, et al., 2006; Lewis, et al., 2006). However, this study
only showed a trend of improvement for negative symptoms on clozapine than
risperidone and typical antipsychotics treatments. We could not rule out that the
potential bias of prescribers for clozapine group in wishing to treat the negative
symptoms, which might have affected the results. Also, it is possible that the clozapine
group could be more treatment resistant because of prescribing bias. This limitation
should be remedied in the future investigation.

This study has some limitations. Firstly, the findings should be regarded as preliminary
due to the cross-sectional study design in our patients with chronic schizophrenia.
Secondly, typical APDs were not classified further due to our limited sample sizes, so
we could not compare the effects of each typical APD on cognitive function with the
effects of clozapine or risperidone. Thirdly, since this research is a phenomenological
study, we cannot explain the real pharmacological effects of these APDs. Fourthly, we
cannot completely rule out the impacts of anticholinergic drug on cognition among
these examined groups, despite the appropriate management of the statistical analysis
controlling for this variable. Fifthly, the dosages of antipsychotic drugs used and the comedication antiparkinsonian used were not controlled and were chosen by the treating
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physician based on individual clinical preferences. We cannot rule out the impacts of
individual clinical preferences for this study.

In conclusion, during long-term APDs medication, patients with chronic schizophrenia
showed significant cognitive deficits than healthy controls in almost all of the examined
cognitive domains, except for the visuospatial/constructional index. Individuals taking
clozapine showed worse immediate and delayed memory than typical APDs, but
improved language compared with risperidone. An improved understanding of the
differential effects of APDs on cognition would facilitate optimal treatment strategies to
maintain or improve cognitive function in patients with schizophrenia and provide an
important guide for psychiatrists and health carers to treat and care for these patients.
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Table-1

Table 1 Demographic and clinical information of healthy controls, clozapine, risperidone and typical antipsychotics
F or X2

p

95/17

1.6

0.143

49.5±9.6

50.3±8.0

1.4

0.245

9.4±4.3

9.3±2.0

8.9±2.0

0.7

0.587

25.9±3.9

24.9±3.8

24.4±3.5

24.3±4.6

1.8

0.114

Smoking (yes/no)

117/42

147/68

59/32

82/30

4.9

0.089

Diabetes (yes/no)

NA

34/181

9/82

21/91

2.7

0.512

Fast glucose (mmol/l)

NA

5.3±1.1

5.0±0.6

5.1±0.7

1.6

0.131

Cholesterol (mmol/l)

NA

4.4±1.0

4.2±0.9

4.5±1.0

1.8

0.154

Triglyceride (mmol/l)

NA

2.0±1.2**

1.4±0.8

1.6±1.0

9.5

0.000

High density lipoprotein (mmol/l)

NA

1.2±0.3##

1.3±0.3

1.4±0.7

7.1

0.001

Low density lipoprotein (mmol/l)

NA

2.6±0.7

2.5±0.5

2.8±0.6

2.3

0.289

Healthy controls

Clozapine

Risperidone

Typical antipsychotics

(n=159)

(n=215)

(n=91)

(n=112)

132/27

182/33

79/12

Age (years)

49.1±9.3

48.6±9.4

Education (years)

9.4±3.1

BMI (kg/m2)

Gender (M/F)

Mean±SD. *indicates the comparison between clozapine and risperidone or typical antipsychotics: **p<0.01. #indicates the comparison
between clozapine and typical antipsychotics: ##p<0.01.

Table-2

Table 2 Characteristics of patients with chronic schizophrenia on long-term treatment with clozapine, risperidone and
typical antipsychotics
F or X2

p

26.5±8.8

0.675

0.510

419.4±116.1

409.2±184.1

0.994

0.372

11.6±4.8

12.3±5.6

11.2±4.7

1.321

0.268

Score on negative symptom scale

21.3±7.0

22.9±7.9

22.8±7.4

2.370

0.095

Score on general psychopathology scale

25.0±5,8

26.0±5.9

25.4±5.1

0.964

0.382

Total PANSS score

57.8±14.4

61.1±15.2

59.5±13.0

1.851

0.158

Antiparkinsonian drugs (trihexyphenidyl) (yes/no)

18/197***

43/48

60/52

100.3

0.000

Clozapine

Risperidone

Typical antipsychotics

(n=215)

(n=91)

(n=112)

25.3±9.6

26.1±9.6

428.3±142.9

Score on positive symptom scale

Duration of illness (years)
Antipsychotic dose (CPZ equivalents)

Mean±SD.

*

indicates the comparison between clozapine and risperidone or typical antipsychotics:

CPZ=chlorpromazine.

***

p<0.001.

Table-3

Table 3 The levels of cognitive function in healthy controls, clozapine, risperidone and typical antipsychotics
Cognitive index

Healthy controls

Clozapine

Risperidone

Typical antipsychotics

Main analyses

(n=159)

(n=215)

(n=91)

(n=112)

F(p value)

Immediate memory

74.9±16.9

58.3±16.6***++

59.5±17.6***

62.7±16.8***

12.4(0.000)

Visuospatial/construction

81.0±14.4

80.5±18.3

78.4±18.7

79.2±19.0

1.1(0.272)

Language

94.6±11.3

84.5±15.6***##

78.6±17.4***

81.8±13.8***

13.4(0.000)

Attention

86.7±17.4

73.1±16.1***

73.1±20.5***

74.3±17.7***

4.3(0.005)

Delayed memory

87.5±13.9

66.2±19.7***++

67.1±19.5***

70.9±20.4***

24.5(0.000)

Total RBANS scores

80.3±13.9

66.1±14.7***

65.5±16.5***

66.7±15.8***

12.1(0.000)

Mean±SD. *indicates the comparison between healthy controls with clozapine or risperidone or typical antipsychotics:
***p<0.001. +indicates the comparison between clozapine and typical antipsychotics:
between clozapine and risperidone: ##p<0.01.

++

p<0.01. #indicates the comparison

